Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anna Rightmire"'
Publikováno v:
Clinical Infectious Diseases. 48:1323-1326
This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a16c6bdd7da4f28b604be41bd01abd7
https://doi.org/10.1086/597776
https://doi.org/10.1086/597776
Autor:
Anna Rightmire, Beatriz Grinsztejn, Margaret Johnson, Kenneth A. Lichtenstein, Linda Odeshoo, Claudia Rodriguez, Edwin DeJesus, Victoria Wirtz, Jeffrey Coco, Adriano Lazzarin, Colin McLaren
Publikováno v:
AIDS (London, England). 20(5)
Background: In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aefe98eb229c6ae5c7ab349819ef214
https://pubmed.ncbi.nlm.nih.gov/16514301
https://pubmed.ncbi.nlm.nih.gov/16514301
Autor:
Margaret Johnson, Serap Sankoh, R B Wilber, Edwin DeJesus, Jeffrey Coco, Adriano Lazzarin, Claudia Rodriguez, Kenneth A. Lichtenstein, Anna Rightmire, Beatriz Grinsztejn
Publikováno v:
Scopus-Elsevier
OBJECTIVE: To evaluate atazanavir/ritonavir (ATV/RTV) (300/100 mg) once daily, atazanavir/saquinavir (ATV/SQV) (400/1200 mg) once daily, and lopinavir/ritonavir (LPV/RTV) (400/100 mg) twice daily, each with tenofovir (300 mg) once daily and a nucleos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86e216183a48d12947cea5630f1ca24e
https://pubmed.ncbi.nlm.nih.gov/15821394
https://pubmed.ncbi.nlm.nih.gov/15821394